Committed to developing and commercializing innovative therapeutics to improve the lives of people with serious retinal diseases. $EYPT
Watertown, MA
Joined March 2013
- Tweets2.5K
- Following1.7K
- Followers1.5K
- Likes306
Pinned Tweet
When it comes to matters of sight, innovation is our vision.
We’re advancing a potential novel multi-mechanism of action for wet AMD and DME - the largest retinal disease markets where there is a significant need for new therapeutic options.
See more on our programs: eyepoint.bio/our-programs/?u…
EyePoint announced a strategic prioritization designed to reduce operating expenses and focus resources on its late-stage program for DURAVYU in diabetic macular edema (DME) through its Phase 3 readouts in 4Q 2027.
Learn more here: investors.eyepoint.bio/news-…
Today, EyePoint reported topline results from LUCIA, the second of two pivotal Phase 3 clinical trials for DURAVYUTM for the treatment of wet AMD.
Learn more here: lnkd.in/g8D-NBHA
At #RetinaSociety2026, four presentations added depth to the DURAVYU story with new and incremental data, including Phase 3 LUGANO analyses on vision, anatomy, treatment burden, and safety with repeat dosing, alongside mechanistic and real-world insights.
eyepoint.bio/scientific-publ…
The EyePoint team is hitting the road for upcoming medical meetings! We’re eager to connect with retina specialists and colleagues around the world.
It’s #NationalHealthyAgingMonth! DYK: Wet AMD and DME become more common with age.
Learn more about our pipeline and how we’re working to protect the vision of aging eyes: eyepoint.bio/our-programs/
What do our LUGANO Phase 3 results mean for wet AMD patients, and what comes next? Our Chief Strategic Science Officer, Dr. Tarek Hassan, joined ‘The Spotlight Series’ to discuss the data in detail, and why we’re excited for the LUCIA trial.
Tune in here: ophthalmology360.com/retinac…
What do the LUGANO results mean for the future of DURAVYU in wet AMD?👁️
🎙️Mario Nacinovich and Tarek Hassan, MD, unpack the data, treatment burden, safety, and what’s next for DURAVYU.
Listen here: ophthalmology360.com/retinac…
#Retina #WetAMD #Ophthalmology
The EyePoint team is NYC bound! We're heading to several investor conferences to connect with industry leaders and share updates on our progress.
National Eye Exam Month just ended – have you scheduled yours? Early detection for wet AMD and DME means early intervention and a higher chance of protecting long-term vision. Book your exam today!
Learn more about EyePoint's clinical trial programs: eyepoint.bio/our-programs/
Our President & CEO, Jay S. Duker, M.D., sat down with @RetinalPhys to discuss the compelling LUGANO topline results, which demonstrate the promise of sustained-release TKIs in wet AMD.
Check out the full interview here: retinalphysician.com/issues/…
Today, EyePoint announced topline results from LUGANO, the first of two pivotal Phase 3 clinical trials for DURAVYU™ for the treatment of wet AMD.
Learn more here: investors.eyepoint.bio/news-…
#InvestorNews: #EYPT reported Q2 2026 financial results and highlighted recent corporate developments.
See more here: investors.eyepoint.bio/news-…
Celebrating our outstanding 2026 summer interns on #NationalInternDay!
Thank you for the curiosity, energy, and fresh perspectives you’re all bringing to EyePoint. #FormulateYourFuture
EyePoint has completed enrollment in both pivotal Phase 3 trials of DURAVYU™ for the treatment of DME. We look forward to continuing to develop this potential therapy, with topline data expected in 4Q 2027.
Learn more here: investors.eyepoint.bio/news-…
For patients with wet AMD and DME, frequent injections take a toll. At EyePoint, we’re developing potential therapies to help alleviate this burden.
Learn more here: eyepoint.bio/our-programs/
TODAY! EyePoint’s Mike Campbell joins other industry experts to discuss how to successfully navigate the shift to commercial readiness.
Registration is still open: biospace.com/events/register…
Last week, the EyePoint team gathered at Kimball Farm for our summer picnic. It was a wonderful afternoon filled with great food, fun activities, and quality time with the people who make this company so special. Thanks to everyone who joined us!
Registration is open for @BioSpace’s webinar on July 22 with EYPT’s Mike Campbell to discuss how to effectively scale a team as a company prepares to bring a product to market.
Register here: biospace.com/events/register…
We’re thrilled to welcome Tarek S. Hassan, M.D., to EyePoint as Chief Strategic Science Officer. His 35+ years in ophthalmology couldn't come at a better time, with our topline Phase 3 wet AMD data expected starting this quarter.
Learn more: investors.eyepoint.bio/news-…
Montreal, here we come! We're looking forward to connecting with the retina community at the ASRS 44th Annual Meeting to exchange ideas and explore new, innovative ways to advance treatment and improve patient outcomes.
Today, on #America250, we celebrate the freedom to innovate and the spirit of discovery that continues to drive progress.
Happy #FourthOfJuly from EyePoint!
